Plain-English translation of NCT07405476 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new drug called to see if it can help shrink colon and rectal cancers before surgery. The medication targets tumors that have a specific marker called HER2 and a particular genetic pattern. Patients in this study will receive the medication through an IV infusion every two weeks before having surgery to remove their cancer.
Most colorectal cancers with the HER2 marker are hard to treat and have limited options. This trial is exploring whether this medication could be given before surgery to shrink tumors and improve outcomes, potentially making surgery more effective and giving patients a better chance at long-term survival.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the medication through an IV infusion lasting about 90 to 150 minutes every two weeks. Depending on whether your cancer is in your colon or rectum, you will receive either 4 or up to 12 cycles of treatment before undergoing surgery to remove your cancer. Throughout the study, you will have regular blood tests, imaging scans (CT or MRI), heart imaging, and possibly a biopsy to help doctors track how well the medication is working and monitor your health and safety.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States